Hematology/Oncology

A 53-year-old woman presented with a 3-month history of worsening vascular skin lesions and a 1-month history of fever. A skin biopsy revealed intravascular aggregation of round, atypical lymphocytes.

Mirvetuximab soravtansine-gynx is an antibody–drug conjugate targeting FRαあるふぁ. Among women with FRαあるふぁ-positive, platinum-resistant ovarian cancer, median overall survival was 16.46 months with MIRV and 12.75 months with chemotherapy.

In this issue of the Journal, Fakih et al.¹ report the results from CodeBreaK 300, a phase 3 trial of the selective Kirsten rat sarcoma viral oncogene homologue (KRAS ) glycine-to-cysteine mutation at codon 12 (KRAS G12C) inhibitor sotorasib in combination with the epidermal growth...

The combination of the G12C-specific KRAS inhibitor sotorasib plus the anti-EGFR antibody panitumumab was superior to standard care in patients with chemorefractory KRAS-mutated colorectal cancer.

A 29-year-old man with sickle cell disease, which had been complicated by vaso-occlusive events and osteonecrosis leading to hip arthroplasty, was admitted because of hip pain. A diagnosis was made.

When Mr. C. is diagnosed with head and neck cancer, he discovers that undergoing cancer care while engaged in the methadone-clinic system is far more complicated than it should be.

Tarlatamab, a bispecific T-cell engager targeting DLL3 and CD3, led to an objective response in 40% of patients, with 68% alive at 9 months. Cytokine-release syndrome, mainly of low severity, occurred in 51%.

The addition of amivantamab to chemotherapy in patients with advanced non–small-cell lung cancer with EGFR exon 20 insertions resulted in significantly longer progression-free survival.

A 30-year-old man presented with a 4-month history of white lines across his fingernails. The nail changes had first appeared midway through six cycles of systemic chemotherapy for the treatment of lymphoma.

In the decades since World War II, the Radiation Effects Research Foundation has elucidated the health effects of nuclear radiation, providing a detailed record of the horrors of nuclear war.

A trial comparing osimertinib plus chemotherapy with osimertinib showed improved progression-free survival with the combination. At 2 years, progression-free survival was 57% with the combination and 41% with monotherapy.

A 53-year-old man presented with an itchy rash, Raynaud’s phenomenon, and dysphagia. There were firm, waxy papules across his forehead and fingers. Laboratory testing identified IgG-λらむだ monoclonal gammopathy.

Targeted therapy has improved prognoses for patients with advanced non–small-cell lung cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations. The seminal trial that established precision medicine for EGFR-mutated NSCLC was the Iressa Pan-Asia Study (IPASS),¹ and a second trial, AURA3, showed that...

Treatment with erdafitinib, a pan-FGFR inhibitor, resulted in significantly longer median overall survival than standard chemotherapy among previously treated patients with bladder cancer whose tumors had FGFR alterations.

Is it ethically acceptable to obtain tissue from healthy volunteers to enable comparisons with tissue from patients? The answer may depend on the accessibility of the tissue in question.

In this trial of primary treatment for advanced RET fusion–positive NSCLC, median progression-free survival was 24.8 months with selpercatinib and 11.7 months with chemotherapy with or without pembrolizumab.

Selpercatinib, an oral, selective, brain-penetrant RET kinase inhibitor, was compared with multikinase inhibitors in advanced medullary thyroid cancer. At 12 months, progression-free survival was 86.8% and 65.7%, respectively.

Although medullary thyroid cancer accounts for less than 5% of thyroid cancers, it deserves attention because of its phenotypic heterogeneity, its often aggressive behavior, and the long-term lack of curative postoperative treatment. In 25% of cases, medullary thyroid cancer may be part of a rare genetic tumor syndrome, multiple endocrine...

This editorial describes the science behind a phase 3 trial of selpercatinib to treat patients with RET fusion–positive non–small-cell lung cancer.

Continuous heart rhythm monitoring with cardiac implantable devices has shown that atrial tachyarrhythmias, termed high-rate episodes (AHREs), occur in approximately one third of device carriers.^1,2 AHRE definitions vary across studies, but cutoffs of an intracardiac atrial frequency of at least 180 bpm with a duration of 5 minutes...